世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

臨床試験市場：フェーズ別（フェーズI、II、III）、サービスタイプ別（ラボラトリー、分析試験、患者募集、プロトコールデザイン）、治療領域別（腫瘍学、循環器学、神経学）、用途別（ワクチン、mAbs、CGT） - 2028年までの世界予測


Clinical Trials Market by Phase (Phase I, II, III), Service Type (Laboratory, Analytical Testing, Patient Recruitment, Protocol Designing), Therapeutic Area (Oncology, Cardiology, Neurology), and Application (Vaccine, mAbs, CGT) - Global Forecast to 2028

世界の臨床試験市場は、2023年の482億米ドルから2028年には732億米ドルに達すると予測され、2023年から2028年の予測期間中の年平均成長率は8.7%である。この市場の成長は、特殊な検査サービスに対する需要の増加... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年9月8日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		342 359 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の臨床試験市場は、2023年の482億米ドルから2028年には732億米ドルに達すると予測され、2023年から2028年の予測期間中の年平均成長率は8.7%である。この市場の成長は、特殊な検査サービスに対する需要の増加に起因している。企業は、液体クロマトグラフィー質量分析（LC/MS）、RNA配列決定、遺伝子発現分析、コンペンディア原料の湿式化学分析、誘導結合質量分析（ICP-MS）による微量金属分析など、専門的な検査サービスのアウトソーシングをますます進めている。これらの検査には高度な機器と熟練した専門家が必要である。設備や人件費を削減するため、製薬企業やバイオ医薬品企業は、これらの専門的な検査サービスをCRO（医薬品開発業務受託機関）にアウトソーシングすることを好んでいる。
"2022年の用途別シェアは低分子セグメントが最大"
2022年、世界の臨床試験市場において、低分子セグメントはアプリケーション別で最大のシェアを占めた。低分子は、心血管疾患から感染症、がんに至るまで、幅広い治療領域をカバーしている。この汎用性により、さまざまな病態にわたる多様な臨床試験が可能になる。低分子の開発プロセスは確立されており、米国FDAのような規制機関に理解されている。このような慣れが承認プロセスを迅速化し、製薬会社がこれらの化合物の臨床試験に投資することを促している。これらの要因が、2022年の同セグメントの優位性に寄与している。
"2023-2028年の予測期間中、米国が引き続き臨床試験市場を支配している。"
2022年の北米の臨床試験市場は米国が支配した。米国の臨床試験市場が大きなシェアを占めているのは、同国で実施される臨床試験や創薬活動の数が多いことに加え、製薬・バイオ医薬品部門に最先端の研究開発インフラが整備されているためと考えられる。米国は臨床試験の世界的なハブとして機能しており、医薬品開発研究の大部分は米国で実施されている。この傾向は、強固な規制の枠組みと高度に発達した病院インフラに起因している。ClinicalTrials.govによると、2023年8月現在、登録された臨床試験は世界で463,610件に達している。注目すべきは、このうち3分の1を占める165,148件の登録臨床研究が米国内で終了していることである。

本レポートのために行われた主なインタビューは以下のように分類される：

- 回答者別供給側40％、需要側60
- 役職別管理職 - 45%、CXOおよび取締役 - 30%、経営幹部 - 25
- 地域別北米40％、欧州25％、アジア太平洋地域20％、中南米10％、中東・アフリカ5
レポート掲載企業一覧
- IQVIA Inc.
- ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス（米国）
- Syneos Health (米国)
- ウーシー・アプテック（中国）
- チャールズ・リバー・ラボラトリーズ（米国）
- パレクセル・インターナショナル・コーポレーション（米）
- サーモフィッシャーサイエンティフィック（米）
- ICON plc（アイルランド）
- メドスペース（米国）
- ACMグローバル・ラボラトリーズ（米）
- アドバンストクリニカル（米国）
- SGS（スイス）
- フロンテッジラボ（米国）
- PSI（スイス）
- バイオアジャイル（インド）
- フォートレア社（米国）
- クリニカル・トライアル・サービス（オランダ）
- ワールドワイド・クリニカル・トライアルズ（米国）
- ペップグラ（英国）
- CTIクリニカル・トライアル＆コンサルティング（米国）
- ダブ・クオリティ・ソリューションズ（英国）
- ファーマ・クリニカル・リサーチ（米国）
- セレリオン（米国）
- ノボテック（オーストラリア）
- クリニカル・アメリカズ（日本）
調査範囲
この調査レポートは、臨床試験市場をフェーズ別（フェーズIII、フェーズII、フェーズIV、フェーズI）、サービスタイプ別（ラボサービス、生物分析試験サービス、分散型臨床試験サービス、患者募集、施設特定、分析試験サービス、臨床試験供給＆ロジスティックサービス、プロトコル設計、臨床試験データ管理サービス、医療機器試験サービス、その他サービス）、治療領域別（腫瘍学、感染症、神経学、代謝疾患、免疫学、循環器学、遺伝性疾患、女性の健康、その他）、用途別（低分子、モノクローナル抗体、ワクチン、細胞・遺伝子治療、その他）、地域別（北米、欧州、アジア太平洋、中南米、中東・アフリカ）。本レポートでは、臨床試験市場の成長に影響を与える促進要因、動向、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。臨床試験市場に関連する新規上市、M&A、最近の動向。
レポート購入の主な利点
本レポートは、臨床試験市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートにより、関係者は市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得ることができます。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（パイプラインにある医薬品の増加、医薬品研究開発への投資の増加、臨床試験数の増加）、阻害要因（臨床試験のための熟練した専門家の不足、革新的な分子に対する独自の試験アプローチの必要性）、機会（生物製剤およびバイオシミラーの良好な見通し、専門的な試験サービスに対する需要の増加）、市場の成長に影響を与える傾向（創薬へのAIベースのツールの採用）の分析。
- サービスの開発/革新：臨床試験市場で新たに開始されたサービスに関する詳細な洞察
- 市場開発：有利な市場に関する包括的な情報 - 当レポートは様々な地域の市場を分析しています。
- 市場の多様化：臨床試験市場における新サービス、未開拓の地域、最近の開発、投資に関する詳細な情報
- 競合評価：IQVIA Inc.（米国）、Laboratory Corporation of America Holdings（米国）、Syneos Health（米国）、WuXi AppTec（中国）、Charles River Laboratories（米国）、Parexel International Corporation（米国）、Thermo Fisher Scientific Inc.(米国）、ICON plc（アイルランド）、Medpace（米国）、ACM Global Laboratories（米国）、Advanced Clinical（米国）、SGS（スイス）、Frontage Labs（米国）、PSI（スイス）、Bioagile（インド）、Fortrea Inc.

ページTOPに戻る


目次

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
1.3.2 YEARS CONSIDERED 42
1.3.3 CURRENCY CONSIDERED 42
1.4 LIMITATIONS 42
1.5 STAKEHOLDERS 43
1.6 SUMMARY OF CHANGES 43
1.6.1 RECESSION IMPACT 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
FIGURE 1 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 45
FIGURE 2 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES 46
2.2 MARKET SIZE ESTIMATION 47
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 47
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 48
FIGURE 5 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022 48
2.2.1 INSIGHTS FROM PRIMARIES 50
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 50
2.2.2 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, THERAPEUTIC AREA, AND APPLICATION) 50
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 50
2.2.3 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, AND THERAPEUTIC AREA) 51
2.3 GROWTH FORECAST 51
FIGURE 8 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2023–2028 52
FIGURE 9 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES 52
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.5 RESEARCH ASSUMPTIONS 54
2.6 RISK ANALYSIS 54
2.7 CLINICAL TRIALS MARKET: RECESSION IMPACT ANALYSIS 54
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 54
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 55
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 55
3 EXECUTIVE SUMMARY 57
FIGURE 11 CLINICAL TRIALS MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 12 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 58
FIGURE 13 CLINICAL TRIALS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 58
FIGURE 14 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2023 VS. 2028 (USD MILLION) 59
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET 60
4 PREMIUM INSIGHTS 61
4.1 CLINICAL TRIALS MARKET OVERVIEW 61
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO DRIVE MARKET 61
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2022) 62
FIGURE 17 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2022 62
4.3 BIOANALYTICAL SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 63
FIGURE 18 CELL-BASED ASSAYS TO DOMINATE MARKET TILL 2028 63
4.4 CLINICAL TRIALS MARKET SHARE, BY THERAPEUTIC AREA, 2023-2028 63
FIGURE 19 ONCOLOGY TO HOLD LARGEST MARKET SHARE TILL 2028 63
4.5 CLINICAL TRIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 64
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 21 CLINICAL TRIALS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 65
TABLE 4 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
5.2.1 DRIVERS 66
5.2.1.1 Increasing drugs in pipeline and rising investments in pharmaceutical R&D 66
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 67
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2023 67
5.2.1.2 Increasing number of clinical trials 68
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2022) 68
5.2.1.3 High cost of in-house drug development 68
FIGURE 25 DISTRIBUTION OF IN-HOUSE AND OUTSOURCING SERVICES EXPENDITURE IN GLOBAL PHARMA MARKET, 2014–2023 (% DISTRIBUTION) 69
5.2.1.4 Rising prevalence of orphan and rare diseases 69
FIGURE 26 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023) 70
FIGURE 27 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHES WITH ORPHAN DRUG DESIGNATION, 2012–2022 70
5.2.2 OPPORTUNITIES 71
5.2.2.1 Favorable outlook for biologics and biosimilars 71
FIGURE 28 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022) 71
TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022 71
FIGURE 29 BIOSIMILAR APPROVALS AND LAUNCHES, 2015–2022 72
5.2.2.2 Rising demand for specialized testing services 72
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 73
FIGURE 30 NUMBER OF ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (AS OF APRIL 2023) 73
FIGURE 31 GENE AND CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENTS, BY REGION (AS OF 2022) 74
5.2.3 CHALLENGES 74
5.2.3.1 Shortage of skilled professionals for clinical trials 74
5.2.3.2 Need for unique testing approaches for innovative molecules 74
5.2.4 TRENDS 75
5.2.4.1 Adoption of AI-based tools for drug discovery 75
5.2.4.2 Increasing outsourcing activities in emerging Asian economies 76
5.2.4.3 Integrated end-to-end R&D service solutions 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 32 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 77
5.4 VALUE CHAIN ANALYSIS 77
FIGURE 33 VALUE CHAIN ANALYSIS OF CLINICAL TRIALS 79
5.5 INDICATIVE PRICING ANALYSIS 79
TABLE 6 PHASE 3 ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES) 80
TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN-EUROPE) 81
5.6 ECOSYSTEM ANALYSIS 82
FIGURE 34 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET 82
TABLE 8 OVERALL MARKET ECOSYSTEM FOR CLINICAL TRIALS 83
5.7 TECHNOLOGY ANALYSIS 84
FIGURE 35 IMPORTANCE OF TECHNOLOGY ADOPTION IN CLINICAL TRIALS 85
5.8 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 9 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.8.1 THREAT OF NEW ENTRANTS 86
5.8.2 THREAT OF SUBSTITUTES 86
5.8.3 BARGAINING POWER OF BUYERS 86
5.8.4 BARGAINING POWER OF SUPPLIERS 86
5.8.5 DEGREE OF COMPETITION 86
5.9 REGULATORY ANALYSIS 87
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 13 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 14 CLINICAL TRIALS MARKET REGULATORY SCENARIO, BY COUNTRY/REGION 90
5.10 KEY CONFERENCES AND EVENTS (2023–2024) 94
TABLE 15 CLINICAL TRIALS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024) 94
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 96
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIALS 96
5.11.2 BUYING CRITERIA FOR CLINICAL TRIALS 96
FIGURE 37 KEY BUYING CRITERIA FOR END USERS 96
6 CLINICAL TRIALS MARKET, BY PHASE 97
6.1 INTRODUCTION 98
TABLE 16 CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 98
FIGURE 38 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022 99
6.2 PHASE III 99
6.2.1 RISING PRICES OF PHASE III TRIALS TO DRIVE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES 99
TABLE 17 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE III (2021–2022) 99
TABLE 18 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 19 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 20 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 21 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.3 PHASE II 101
6.3.1 LONG DURATION OF PHASE II STUDIES TO PROVIDE GROWTH OPPORTUNITIES FOR CROS 101
TABLE 22 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE II (2021–2022) 102
TABLE 23 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 24 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 25 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 26 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.4 PHASE IV 104
6.4.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE MARKET 104
TABLE 27 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE IV (2021–2022) 104
TABLE 28 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 29 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 30 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 31 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.5 PHASE I 106
6.5.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES TO BOOST MARKET 106
TABLE 32 OVERVIEW OF DRUGS IN PHASE I STUDIES (2021–2022) 106
TABLE 33 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 34 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 35 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 36 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE 109
7.1 INTRODUCTION 110
TABLE 37 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 110
7.2 LABORATORY SERVICES 110
7.2.1 RISING IMPORTANCE OF LAB SERVICES AND NEED TO ENSURE REGULATORY COMPLIANCE TO DRIVE MARKET 110
TABLE 38 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 111
TABLE 39 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 40 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 41 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 42 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
7.3 BIOANALYTICAL TESTING SERVICES 112
TABLE 43 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 44 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 45 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 46 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 47 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7.3.1 CELL-BASED ASSAYS 115
7.3.1.1 Rising number of providers offering customized assay testing to boost growth 115
TABLE 48 CELL-BASED ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 49 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 50 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 51 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
7.3.2 VIROLOGY TESTING 116
7.3.2.1 Rising uptake of in vitro virology assays to develop antiviral pharmaceuticals to favor market 116
TABLE 52 VIROLOGY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 53 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 54 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 55 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
7.3.3 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES 118
7.3.3.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to drive market 118
TABLE 56 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 57 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 58 EUROPE: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 59 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
7.3.4 PK/PD TESTING 120
7.3.4.1 Growing importance of drug pharmacokinetics to boost demand 120
TABLE 60 PK/PD TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 61 NORTH AMERICA: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 62 EUROPE: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 63 ASIA PACIFIC: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
7.3.5 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION 122
7.3.5.1 Biopharma industry preference for outsourcing method validation to drive market 122
TABLE 64 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 65 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 66 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 67 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
7.3.6 BIOMARKER TESTING 124
7.3.6.1 Growing emphasis on biomarker testing to develop personalized medicines and CDx to augment market 124
TABLE 68 BIOMARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 69 NORTH AMERICA: BIOMARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 70 EUROPE: BIOMARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 71 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
7.3.7 OTHER BIOANALYTICAL TESTING SERVICES 126
TABLE 72 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 73 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 74 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 75 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
7.4 DECENTRALIZED CLINICAL TRIAL SERVICES 127
7.4.1 HIGH DEMAND FOR DCT ATTRIBUTED TO ADVANCEMENTS IN DIGITAL HEALTH TECHNOLOGIES 127
TABLE 76 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 77 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 79 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
7.5 PATIENT RECRUITMENT SERVICES 129
7.5.1 GROWING NEED FOR PATIENT-CENTRIC CLINICAL TRIAL SERVICES TO SUPPORT DEMAND 129
TABLE 80 OVERVIEW OF PATIENT RECRUITMENT SERVICE PROVIDERS 130
TABLE 81 PATIENT RECRUITMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 82 NORTH AMERICA: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 EUROPE: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 84 ASIA PACIFIC: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
7.6 SITE IDENTIFICATION SERVICES 132
7.6.1 INTRODUCTION OF DIGITAL TECHNOLOGIES ENABLING DATA VARIABILITY TO DRIVE MARKET 132
TABLE 85 SITE IDENTIFICATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 86 NORTH AMERICA: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 87 EUROPE: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
7.7 ANALYTICAL TESTING SERVICES 134
7.7.1 INCREASING DEMAND FOR ANALYTICAL TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET 134
TABLE 89 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 90 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 91 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 92 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
7.8 SUPPLY & LOGISTICS SERVICES 136
7.8.1 USAGE OF ADVANCED DATA ANALYTICS IN CLINICAL TRIAL SUPPLY MANAGEMENT TO DRIVE MARKET 136
TABLE 93 SUPPLY & LOGISTICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 94 NORTH AMERICA: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 95 EUROPE: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 96 ASIA PACIFIC: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
7.9 PROTOCOL DESIGNING SERVICES 138
7.9.1 NEED FOR PLANNING SUPPORT TO BOOST DEMAND FOR PROTOCOL DESIGN 138
TABLE 97 PROTOCOL DESIGNING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 98 NORTH AMERICA: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 99 EUROPE: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 100 ASIA PACIFIC: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
7.10 DATA MANAGEMENT SERVICES 140
7.10.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR OVER FORECAST PERIOD 140
TABLE 101 DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 140
TABLE 102 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 103 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 104 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 105 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
7.11 MEDICAL DEVICE TESTING SERVICES 143
7.11.1 INCREASING MEDICAL DEVICE R&D TO DRIVE MARKET 143
TABLE 106 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 107 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 108 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 109 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
7.12 OTHER SERVICES 145
TABLE 110 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 111 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 112 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 113 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
8 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA 148
8.1 INTRODUCTION 149
TABLE 114 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 149
8.2 ONCOLOGY 149
8.2.1 ONCOLOGY TO DOMINATE MARKET DUE TO RISING INCIDENCE OF CANCER 149
FIGURE 39 US CANCER INCIDENCE IN MALES, BY TYPE (2022) 150
FIGURE 40 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022) 150
FIGURE 41 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010–2021 (THOUSAND) 151
TABLE 115 NEW FDA-APPROVED ONCOLOGY DRUGS (2023) 151
TABLE 116 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 117 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 118 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 119 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
8.3 INFECTIOUS DISEASES 154
8.3.1 INFECTIOUS DISEASES TO HOLD SECOND-LARGEST MARKET SHARE, BY THERAPEUTIC AREA 154
TABLE 120 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 154
TABLE 121 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 122 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 123 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
8.4 NEUROLOGY 155
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET 155
TABLE 124 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 156
TABLE 125 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 126 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 127 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 128 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 158
8.5 METABOLIC DISORDERS 158
8.5.1 RISING DIABETES INCIDENCE TO DRIVE MARKET 158
FIGURE 42 INCREASE IN DIABETES CASES, 2000–2045 (MILLION INDIVIDUALS) 158
TABLE 129 CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 159
TABLE 130 NORTH AMERICA: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 131 EUROPE: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 132 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 160
8.6 IMMUNOLOGY 160
8.6.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS TO BOOST OUTSOURCING 160
TABLE 133 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) 161
TABLE 134 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 135 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 136 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 137 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
8.7 CARDIOLOGY 162
8.7.1 HIGH MORTALITY RATES TO DRIVE DEVELOPMENT OF NEW TREATMENTS 162
TABLE 138 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023) 163
TABLE 139 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 140 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 141 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 142 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
8.8 GENETIC DISEASES 165
8.8.1 GOVERNMENT SUPPORT FOR RARE & GENETIC DISEASE THERAPEUTICS TO BOOST MARKET 165
TABLE 143 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 144 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 145 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 146 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
8.9 WOMEN’S HEALTH 166
8.9.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL DEMAND 166
TABLE 147 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 148 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 149 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 150 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 168
8.10 OTHER THERAPEUTIC AREAS 168
TABLE 151 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022) 169
TABLE 152 CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 169
TABLE 153 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 154 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 155 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
9 CLINICAL TRIALS MARKET, BY APPLICATION 171
9.1 INTRODUCTION 172
TABLE 156 CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
9.2 SMALL MOLECULES 172
9.2.1 INVESTMENTS IN SMALL-MOLECULE DEVELOPMENT TO SUPPORT GROWTH 172
TABLE 157 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 159 EUROPE: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 160 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 174
9.3 MONOCLONAL ANTIBODIES 174
9.3.1 GROWING GOVERNMENT SUPPORT FOR MONOCLONAL ANTIBODIES TO DRIVE MARKET 174
TABLE 161 CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 162 NORTH AMERICA: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 163 EUROPE: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 164 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 176
9.4 VACCINES 176
9.4.1 SHIFTING INDUSTRY FOCUS TOWARD CHRONIC DISEASE TREATMENT TO SLOW MARKET GROWTH 176
FIGURE 43 NUMBER OF CLINICAL TRIALS FOR VACCINES (2020–2023) 177
TABLE 165 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 166 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 167 EUROPE: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 168 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 178
9.5 CELL & GENE THERAPY 178
9.5.1 RISING TREND OF OUTSOURCING TO FAVOR MARKET GROWTH 178
FIGURE 44 ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (2022) 179
TABLE 169 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 179
TABLE 170 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 171 EUROPE: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 172 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
9.6 OTHER APPLICATIONS 181
TABLE 173 CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 174 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 175 EUROPE: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 176 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
10 CLINICAL TRIALS MARKET, BY REGION 183
10.1 INTRODUCTION 184
TABLE 177 CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 184
10.2 NORTH AMERICA 184
10.2.1 NORTH AMERICA: RECESSION IMPACT 185
FIGURE 45 NORTH AMERICA: CLINICAL TRIALS MARKET SNAPSHOT 186
TABLE 178 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 179 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 187
TABLE 180 NORTH AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 187
TABLE 181 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 182 NORTH AMERICA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 188
TABLE 183 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
10.2.2 US 189
10.2.2.1 US to hold largest share of North American market over forecast period 189
FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023): US TO HOLD DOMINANT SHARE 190
TABLE 184 US: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 190
TABLE 185 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 191
TABLE 186 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 187 US: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 192
TABLE 188 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
10.2.3 CANADA 193
10.2.3.1 Increasing clinical trial activity to support market growth 193
TABLE 189 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 193
TABLE 190 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 194
TABLE 191 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 192 CANADA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 195
TABLE 193 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
10.3 EUROPE 196
10.3.1 EUROPE: RECESSION IMPACT 196
FIGURE 47 PHARMACEUTICAL INDUSTRY R&D SPENDING IN EUROPEAN COUNTRIES, 2021 (USD MILLION) 197
TABLE 194 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 195 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 198
TABLE 196 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 198
TABLE 197 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 198 EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 199
TABLE 199 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
10.3.2 GERMANY 200
10.3.2.1 Germany to dominate clinical trials market in Europe 200
TABLE 200 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 201
TABLE 201 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 201
TABLE 202 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 203 GERMANY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 202
TABLE 204 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
10.3.3 UK 203
10.3.3.1 Investments in drug discovery services to support market growth 203
FIGURE 48 UK: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION) 204
TABLE 205 UK: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 204
TABLE 206 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 205
TABLE 207 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 208 UK: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
TABLE 209 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 206
10.3.4 FRANCE 207
10.3.4.1 High number of oncology clinical trials to drive market 207
TABLE 210 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 207
TABLE 211 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 208
TABLE 212 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 213 FRANCE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
TABLE 214 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 209
10.3.5 ITALY 210
10.3.5.1 Low drug approval times and growing number of clinical trials to boost market 210
TABLE 215 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 210
TABLE 216 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 211
TABLE 217 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 218 ITALY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 212
TABLE 219 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 212
10.3.6 SPAIN 213
10.3.6.1 Rising R&D expenditure to drive market 213
FIGURE 49 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION) 213
TABLE 220 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 214
TABLE 221 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 214
TABLE 222 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 223 SPAIN: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 215
TABLE 224 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 216
10.3.7 REST OF EUROPE 216
TABLE 225 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 217
TABLE 226 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 218
TABLE 227 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 228 REST OF EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 219
TABLE 229 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220

　

ページTOPに戻る


　

Summary

The global clinical trials market is projected to reach USD 73.2 billion by 2028 from USD 48.2 billion in 2023, at a CAGR of 8.7% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing demand for specialized testing services. Companies are increasingly outsourcing specialized testing services, such as liquid chromatography-mass spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, and trace metal analysis with inductively coupled mass spectrometry (ICP-MS). These tests require advanced equipment and skilled professionals. In an effort to reduce equipment and labor expenses, pharmaceutical and biopharmaceutical enterprises prefer the outsourcing of these specialized testing services to Contract Research Organizations (CROs).
“The small molecules segment accounted for the largest share by application in 2022.”
In 2022, the small molecules segment accounted for the largest share by application in the global clinical trials market. Small molecules cover a wide spectrum of therapeutic areas, from cardiovascular diseases to infectious diseases to cancer. This versatility allows for a diverse range of clinical trials across different medical conditions. The development process for small molecules is well-established and understood by regulatory agencies like the US FDA. This familiarity expedites the approval process and encourages pharmaceutical companies to invest in clinical trials for these compounds. These factors contributed to the dominance of the segment in 2022.
“The US has continued to dominate the clinical trials market during the forecast period of 2023-2028.”
The US dominated the clinical trials market in North America in 2022. The major share of the US clinical trials market can be attributed to the significant number of clinical trials and drug discovery activities conducted in the country, coupled with the presence of state-of-the-art research and development infrastructure within the pharmaceutical and biopharmaceutical sectors. The US serves as a global hub for clinical trials, with a significant portion of drug development research being carried out in the US. This trend is attributed to its robust regulatory framework and highly advanced hospital infrastructure. According to ClinicalTrials.gov, as of August 2023, the global count of registered clinical studies reached 463,610. Notably, one-third of this total, accounting for 165,148 registered clinical studies, were concluded within the US.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 40% and Demand Side 60%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
• IQVIA Inc. (US)
• Laboratory Corporation of America Holdings (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• Parexel International Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• ICON plc (Ireland)
• Medpace (US)
• ACM Global Laboratories (US)
• Advanced Clinical (US)
• SGS (Switzerland)
• Frontage Labs (US)
• PSI (Switzerland)
• Bioagile (India)
• Fortrea Inc. (US)
• Clinical Trial Service (Netherlands)
• Worldwide Clinical Trials (US)
• Pepgra (UK)
• CTI Clinical Trial & Consulting (US)
• Dove Quality Solutions (UK)
• Firma Clinical Research (US)
• Celerion (US)
• Novotech (Australia)
• Clinical Americas (Japan)
Research Coverage:
This research report categorizes the clinical trials market by phase (Phase III, Phase II, Phase IV, and Phase I), by Service Type (Laboratory Services, Bioanalytical Testing Services, Decentralized Clinical Trial Services, Patient Recruitment, Site Identification, Analytical Testing Services, Clinical Trial Supply & Logistic Services, Protocol Designing, Clinical Trial Data Management Services, Medical Device Testing Services, and Other Services), by Therapeutic Area (Oncology, Infectious Diseases, Neurology, Metabolic Disorders, Immunology, Cardiology, Genetic Diseases, Women's Health, and Others) by Application (Small Molecules, Monoclonal Antibodies, Vaccine, Cell & Gene Therapy, and Others) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, trends, challenges, and opportunities, influencing the growth of the clinical trials market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services, key strategies, collaborations, partnerships, and agreements. New launches, mergers and acquisitions, and recent developments associated with the clinical trials market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trials market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing drugs in the pipeline, rising investments in pharmaceutical R&D, and increasing number of clinical trials), restraints (Shortage of skilled professionals for clinical trials, Need for unique testing approaches for innovative molecules), opportunities (Favorable outlook for biologics and biosimilars and Rising demand for specialized testing services), and Trends (Adoption of AI-based tools for drug discovery) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on newly launched services of the clinical trials market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trials market
• Competitive Assessment: In- IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Syneos Health (US), WuXi AppTec (China), Charles River Laboratories (US), Parexel International Corporation (US), Thermo Fisher Scientific Inc. (US), ICON plc (Ireland), Medpace (US), ACM Global Laboratories (US), Advanced Clinical (US), SGS (Switzerland), Frontage Labs (US), PSI (Switzerland), Bioagile (India), Fortrea Inc. (US), and among others in the market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
1.3.2 YEARS CONSIDERED 42
1.3.3 CURRENCY CONSIDERED 42
1.4 LIMITATIONS 42
1.5 STAKEHOLDERS 43
1.6 SUMMARY OF CHANGES 43
1.6.1 RECESSION IMPACT 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
FIGURE 1 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 45
FIGURE 2 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES 46
2.2 MARKET SIZE ESTIMATION 47
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 47
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 48
FIGURE 5 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022 48
2.2.1 INSIGHTS FROM PRIMARIES 50
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 50
2.2.2 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, THERAPEUTIC AREA, AND APPLICATION) 50
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 50
2.2.3 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, AND THERAPEUTIC AREA) 51
2.3 GROWTH FORECAST 51
FIGURE 8 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2023–2028 52
FIGURE 9 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES 52
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.5 RESEARCH ASSUMPTIONS 54
2.6 RISK ANALYSIS 54
2.7 CLINICAL TRIALS MARKET: RECESSION IMPACT ANALYSIS 54
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 54
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 55
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 55
3 EXECUTIVE SUMMARY 57
FIGURE 11 CLINICAL TRIALS MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 12 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 58
FIGURE 13 CLINICAL TRIALS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 58
FIGURE 14 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2023 VS. 2028 (USD MILLION) 59
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET 60
4 PREMIUM INSIGHTS 61
4.1 CLINICAL TRIALS MARKET OVERVIEW 61
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO DRIVE MARKET 61
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2022) 62
FIGURE 17 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2022 62
4.3 BIOANALYTICAL SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 63
FIGURE 18 CELL-BASED ASSAYS TO DOMINATE MARKET TILL 2028 63
4.4 CLINICAL TRIALS MARKET SHARE, BY THERAPEUTIC AREA, 2023-2028 63
FIGURE 19 ONCOLOGY TO HOLD LARGEST MARKET SHARE TILL 2028 63
4.5 CLINICAL TRIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 64
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 21 CLINICAL TRIALS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 65
TABLE 4 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
5.2.1 DRIVERS 66
5.2.1.1 Increasing drugs in pipeline and rising investments in pharmaceutical R&D 66
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 67
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2023 67
5.2.1.2 Increasing number of clinical trials 68
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2022) 68
5.2.1.3 High cost of in-house drug development 68
FIGURE 25 DISTRIBUTION OF IN-HOUSE AND OUTSOURCING SERVICES EXPENDITURE IN GLOBAL PHARMA MARKET, 2014–2023 (% DISTRIBUTION) 69
5.2.1.4 Rising prevalence of orphan and rare diseases 69
FIGURE 26 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023) 70
FIGURE 27 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHES WITH ORPHAN DRUG DESIGNATION, 2012–2022 70
5.2.2 OPPORTUNITIES 71
5.2.2.1 Favorable outlook for biologics and biosimilars 71
FIGURE 28 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022) 71
TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022 71
FIGURE 29 BIOSIMILAR APPROVALS AND LAUNCHES, 2015–2022 72
5.2.2.2 Rising demand for specialized testing services 72
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 73
FIGURE 30 NUMBER OF ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (AS OF APRIL 2023) 73
FIGURE 31 GENE AND CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENTS, BY REGION (AS OF 2022) 74
5.2.3 CHALLENGES 74
5.2.3.1 Shortage of skilled professionals for clinical trials 74
5.2.3.2 Need for unique testing approaches for innovative molecules 74
5.2.4 TRENDS 75
5.2.4.1 Adoption of AI-based tools for drug discovery 75
5.2.4.2 Increasing outsourcing activities in emerging Asian economies 76
5.2.4.3 Integrated end-to-end R&D service solutions 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 32 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 77
5.4 VALUE CHAIN ANALYSIS 77
FIGURE 33 VALUE CHAIN ANALYSIS OF CLINICAL TRIALS 79
5.5 INDICATIVE PRICING ANALYSIS 79
TABLE 6 PHASE 3 ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES) 80
TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN-EUROPE) 81
5.6 ECOSYSTEM ANALYSIS 82
FIGURE 34 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET 82
TABLE 8 OVERALL MARKET ECOSYSTEM FOR CLINICAL TRIALS 83
5.7 TECHNOLOGY ANALYSIS 84
FIGURE 35 IMPORTANCE OF TECHNOLOGY ADOPTION IN CLINICAL TRIALS 85
5.8 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 9 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.8.1 THREAT OF NEW ENTRANTS 86
5.8.2 THREAT OF SUBSTITUTES 86
5.8.3 BARGAINING POWER OF BUYERS 86
5.8.4 BARGAINING POWER OF SUPPLIERS 86
5.8.5 DEGREE OF COMPETITION 86
5.9 REGULATORY ANALYSIS 87
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 13 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 14 CLINICAL TRIALS MARKET REGULATORY SCENARIO, BY COUNTRY/REGION 90
5.10 KEY CONFERENCES AND EVENTS (2023–2024) 94
TABLE 15 CLINICAL TRIALS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024) 94
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 96
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIALS 96
5.11.2 BUYING CRITERIA FOR CLINICAL TRIALS 96
FIGURE 37 KEY BUYING CRITERIA FOR END USERS 96
6 CLINICAL TRIALS MARKET, BY PHASE 97
6.1 INTRODUCTION 98
TABLE 16 CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 98
FIGURE 38 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022 99
6.2 PHASE III 99
6.2.1 RISING PRICES OF PHASE III TRIALS TO DRIVE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES 99
TABLE 17 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE III (2021–2022) 99
TABLE 18 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 19 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 20 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 21 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.3 PHASE II 101
6.3.1 LONG DURATION OF PHASE II STUDIES TO PROVIDE GROWTH OPPORTUNITIES FOR CROS 101
TABLE 22 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE II (2021–2022) 102
TABLE 23 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 24 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 25 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 26 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.4 PHASE IV 104
6.4.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE MARKET 104
TABLE 27 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE IV (2021–2022) 104
TABLE 28 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 29 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 30 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 31 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.5 PHASE I 106
6.5.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES TO BOOST MARKET 106
TABLE 32 OVERVIEW OF DRUGS IN PHASE I STUDIES (2021–2022) 106
TABLE 33 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 34 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 35 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 36 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE 109
7.1 INTRODUCTION 110
TABLE 37 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 110
7.2 LABORATORY SERVICES 110
7.2.1 RISING IMPORTANCE OF LAB SERVICES AND NEED TO ENSURE REGULATORY COMPLIANCE TO DRIVE MARKET 110
TABLE 38 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 111
TABLE 39 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 40 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 41 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 42 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
7.3 BIOANALYTICAL TESTING SERVICES 112
TABLE 43 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 44 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 45 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 46 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 47 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7.3.1 CELL-BASED ASSAYS 115
7.3.1.1 Rising number of providers offering customized assay testing to boost growth 115
TABLE 48 CELL-BASED ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 49 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 50 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 51 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
7.3.2 VIROLOGY TESTING 116
7.3.2.1 Rising uptake of in vitro virology assays to develop antiviral pharmaceuticals to favor market 116
TABLE 52 VIROLOGY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 53 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 54 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 55 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
7.3.3 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES 118
7.3.3.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to drive market 118
TABLE 56 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 57 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 58 EUROPE: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 59 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
7.3.4 PK/PD TESTING 120
7.3.4.1 Growing importance of drug pharmacokinetics to boost demand 120
TABLE 60 PK/PD TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 61 NORTH AMERICA: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 62 EUROPE: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 63 ASIA PACIFIC: PK/PD TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
7.3.5 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION 122
7.3.5.1 Biopharma industry preference for outsourcing method validation to drive market 122
TABLE 64 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 65 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 66 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 67 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
7.3.6 BIOMARKER TESTING 124
7.3.6.1 Growing emphasis on biomarker testing to develop personalized medicines and CDx to augment market 124
TABLE 68 BIOMARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 69 NORTH AMERICA: BIOMARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 70 EUROPE: BIOMARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 71 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
7.3.7 OTHER BIOANALYTICAL TESTING SERVICES 126
TABLE 72 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 73 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 74 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 75 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
7.4 DECENTRALIZED CLINICAL TRIAL SERVICES 127
7.4.1 HIGH DEMAND FOR DCT ATTRIBUTED TO ADVANCEMENTS IN DIGITAL HEALTH TECHNOLOGIES 127
TABLE 76 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 77 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 79 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
7.5 PATIENT RECRUITMENT SERVICES 129
7.5.1 GROWING NEED FOR PATIENT-CENTRIC CLINICAL TRIAL SERVICES TO SUPPORT DEMAND 129
TABLE 80 OVERVIEW OF PATIENT RECRUITMENT SERVICE PROVIDERS 130
TABLE 81 PATIENT RECRUITMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 82 NORTH AMERICA: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 EUROPE: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 84 ASIA PACIFIC: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
7.6 SITE IDENTIFICATION SERVICES 132
7.6.1 INTRODUCTION OF DIGITAL TECHNOLOGIES ENABLING DATA VARIABILITY TO DRIVE MARKET 132
TABLE 85 SITE IDENTIFICATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 86 NORTH AMERICA: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 87 EUROPE: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
7.7 ANALYTICAL TESTING SERVICES 134
7.7.1 INCREASING DEMAND FOR ANALYTICAL TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET 134
TABLE 89 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 90 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 91 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 92 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
7.8 SUPPLY & LOGISTICS SERVICES 136
7.8.1 USAGE OF ADVANCED DATA ANALYTICS IN CLINICAL TRIAL SUPPLY MANAGEMENT TO DRIVE MARKET 136
TABLE 93 SUPPLY & LOGISTICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 94 NORTH AMERICA: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 95 EUROPE: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 96 ASIA PACIFIC: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
7.9 PROTOCOL DESIGNING SERVICES 138
7.9.1 NEED FOR PLANNING SUPPORT TO BOOST DEMAND FOR PROTOCOL DESIGN 138
TABLE 97 PROTOCOL DESIGNING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 98 NORTH AMERICA: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 99 EUROPE: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 100 ASIA PACIFIC: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
7.10 DATA MANAGEMENT SERVICES 140
7.10.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR OVER FORECAST PERIOD 140
TABLE 101 DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 140
TABLE 102 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 103 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 104 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 105 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
7.11 MEDICAL DEVICE TESTING SERVICES 143
7.11.1 INCREASING MEDICAL DEVICE R&D TO DRIVE MARKET 143
TABLE 106 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 107 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 108 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 109 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
7.12 OTHER SERVICES 145
TABLE 110 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 111 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 112 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 113 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
8 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA 148
8.1 INTRODUCTION 149
TABLE 114 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 149
8.2 ONCOLOGY 149
8.2.1 ONCOLOGY TO DOMINATE MARKET DUE TO RISING INCIDENCE OF CANCER 149
FIGURE 39 US CANCER INCIDENCE IN MALES, BY TYPE (2022) 150
FIGURE 40 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022) 150
FIGURE 41 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010–2021 (THOUSAND) 151
TABLE 115 NEW FDA-APPROVED ONCOLOGY DRUGS (2023) 151
TABLE 116 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 117 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 118 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 119 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
8.3 INFECTIOUS DISEASES 154
8.3.1 INFECTIOUS DISEASES TO HOLD SECOND-LARGEST MARKET SHARE, BY THERAPEUTIC AREA 154
TABLE 120 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 154
TABLE 121 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 122 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 123 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
8.4 NEUROLOGY 155
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET 155
TABLE 124 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 156
TABLE 125 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 126 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 127 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 128 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 158
8.5 METABOLIC DISORDERS 158
8.5.1 RISING DIABETES INCIDENCE TO DRIVE MARKET 158
FIGURE 42 INCREASE IN DIABETES CASES, 2000–2045 (MILLION INDIVIDUALS) 158
TABLE 129 CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 159
TABLE 130 NORTH AMERICA: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 131 EUROPE: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 132 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 160
8.6 IMMUNOLOGY 160
8.6.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS TO BOOST OUTSOURCING 160
TABLE 133 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) 161
TABLE 134 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 135 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 136 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 137 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
8.7 CARDIOLOGY 162
8.7.1 HIGH MORTALITY RATES TO DRIVE DEVELOPMENT OF NEW TREATMENTS 162
TABLE 138 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023) 163
TABLE 139 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 140 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 141 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 142 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
8.8 GENETIC DISEASES 165
8.8.1 GOVERNMENT SUPPORT FOR RARE & GENETIC DISEASE THERAPEUTICS TO BOOST MARKET 165
TABLE 143 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 144 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 145 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 146 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
8.9 WOMEN’S HEALTH 166
8.9.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL DEMAND 166
TABLE 147 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 148 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 149 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 150 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 168
8.10 OTHER THERAPEUTIC AREAS 168
TABLE 151 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022) 169
TABLE 152 CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 169
TABLE 153 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 154 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 155 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
9 CLINICAL TRIALS MARKET, BY APPLICATION 171
9.1 INTRODUCTION 172
TABLE 156 CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172
9.2 SMALL MOLECULES 172
9.2.1 INVESTMENTS IN SMALL-MOLECULE DEVELOPMENT TO SUPPORT GROWTH 172
TABLE 157 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 159 EUROPE: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 160 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021–2028 (USD MILLION) 174
9.3 MONOCLONAL ANTIBODIES 174
9.3.1 GROWING GOVERNMENT SUPPORT FOR MONOCLONAL ANTIBODIES TO DRIVE MARKET 174
TABLE 161 CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 162 NORTH AMERICA: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 163 EUROPE: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 164 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 176
9.4 VACCINES 176
9.4.1 SHIFTING INDUSTRY FOCUS TOWARD CHRONIC DISEASE TREATMENT TO SLOW MARKET GROWTH 176
FIGURE 43 NUMBER OF CLINICAL TRIALS FOR VACCINES (2020–2023) 177
TABLE 165 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 166 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 167 EUROPE: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 168 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 178
9.5 CELL & GENE THERAPY 178
9.5.1 RISING TREND OF OUTSOURCING TO FAVOR MARKET GROWTH 178
FIGURE 44 ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (2022) 179
TABLE 169 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 179
TABLE 170 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 171 EUROPE: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 172 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 180
9.6 OTHER APPLICATIONS 181
TABLE 173 CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 174 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 175 EUROPE: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 176 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 182
10 CLINICAL TRIALS MARKET, BY REGION 183
10.1 INTRODUCTION 184
TABLE 177 CLINICAL TRIALS MARKET, BY REGION, 2021–2028 (USD MILLION) 184
10.2 NORTH AMERICA 184
10.2.1 NORTH AMERICA: RECESSION IMPACT 185
FIGURE 45 NORTH AMERICA: CLINICAL TRIALS MARKET SNAPSHOT 186
TABLE 178 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 179 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 187
TABLE 180 NORTH AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 187
TABLE 181 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 182 NORTH AMERICA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 188
TABLE 183 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
10.2.2 US 189
10.2.2.1 US to hold largest share of North American market over forecast period 189
FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023): US TO HOLD DOMINANT SHARE 190
TABLE 184 US: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 190
TABLE 185 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 191
TABLE 186 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 187 US: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 192
TABLE 188 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
10.2.3 CANADA 193
10.2.3.1 Increasing clinical trial activity to support market growth 193
TABLE 189 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 193
TABLE 190 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 194
TABLE 191 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 192 CANADA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 195
TABLE 193 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
10.3 EUROPE 196
10.3.1 EUROPE: RECESSION IMPACT 196
FIGURE 47 PHARMACEUTICAL INDUSTRY R&D SPENDING IN EUROPEAN COUNTRIES, 2021 (USD MILLION) 197
TABLE 194 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 195 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 198
TABLE 196 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 198
TABLE 197 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 198 EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 199
TABLE 199 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
10.3.2 GERMANY 200
10.3.2.1 Germany to dominate clinical trials market in Europe 200
TABLE 200 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 201
TABLE 201 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 201
TABLE 202 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 203 GERMANY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 202
TABLE 204 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
10.3.3 UK 203
10.3.3.1 Investments in drug discovery services to support market growth 203
FIGURE 48 UK: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION) 204
TABLE 205 UK: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 204
TABLE 206 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 205
TABLE 207 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 208 UK: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
TABLE 209 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 206
10.3.4 FRANCE 207
10.3.4.1 High number of oncology clinical trials to drive market 207
TABLE 210 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 207
TABLE 211 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 208
TABLE 212 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 213 FRANCE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
TABLE 214 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 209
10.3.5 ITALY 210
10.3.5.1 Low drug approval times and growing number of clinical trials to boost market 210
TABLE 215 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 210
TABLE 216 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 211
TABLE 217 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 218 ITALY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 212
TABLE 219 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 212
10.3.6 SPAIN 213
10.3.6.1 Rising R&D expenditure to drive market 213
FIGURE 49 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2018–2021 (USD MILLION) 213
TABLE 220 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 214
TABLE 221 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 214
TABLE 222 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 223 SPAIN: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 215
TABLE 224 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 216
10.3.7 REST OF EUROPE 216
TABLE 225 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021–2028 (USD MILLION) 217
TABLE 226 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 218
TABLE 227 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 228 REST OF EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 219
TABLE 229 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

MarketsandMarkets社のPharmaceuticals分野での最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.